Caspogin50 mg/vial

Caspogin is an echinocandin-class antifungal administered intravenously under specialist supervision for serious systemic fungal infections. Indications are classified below by strength of evidence.

Established / FDA-approved uses

• Empirical therapy for presumed fungal infections in febrile, neutropenic patients.
• Candidemia and other Candida infections, including intra-abdominal abscesses, peritonitis, and pleural space infections caused by Candida species.
• Esophageal candidiasis.
• Invasive aspergillosis in patients who are refractory to or intolerant of other antifungal therapies (e.g., amphotericin B formulations or itraconazole).

Use requiring combination or salvage context

• In invasive aspergillosis, Caspogin is used as salvage monotherapy after failure of first-line agents; it is not established as first-line or combination primary therapy for aspergillosis.

Caspogin is not indicated for superficial or minor fungal infections and should be reserved for confirmed or strongly suspected serious systemic fungal disease, consistent with antifungal stewardship principles.

Each vial of Caspofungin Acetate for injection contains caspofungin (as caspofungin acetate) as a sterile, lyophilized (freeze-dried) powder for reconstitution, commonly available in strengths equivalent to 50 mg and 70 mg caspofungin per vial, for single-use intravenous infusion after reconstitution and dilution.

Caspogin is the first agent of the echinocandin class of antifungal drugs. It is a semisynthetic lipopeptide derived from a fermentation product of Glarea lozoyensis and works by disrupting the fungal cell wall. Caspogin is supplied as a lyophilized powder for intravenous infusion and is used in hospital settings for the treatment of serious, invasive fungal infections, particularly in immunocompromised patients.

Caspogin belongs to the echinocandin class of systemic antifungal agents.

Mechanism of Action

Caspofungin Acetate inhibits the synthesis of 1,3-β-D-glucan, an essential polysaccharide component of the cell wall of many pathogenic fungi, including Candida and Aspergillus species. Because 1,3-β-D-glucan is not present in mammalian cells, this mechanism confers a favorable selectivity profile. Loss of cell wall integrity leads to osmotic instability and fungal cell death (fungicidal against Candida, fungistatic against Aspergillus).

Pharmacokinetics

Caspofungin Acetate is administered only by slow intravenous infusion; it is not absorbed orally. It is highly protein-bound, distributes into tissues, and undergoes slow metabolism via hydrolysis and N-acetylation with subsequent excretion mainly in the urine and feces over several days. Its plasma half-life is approximately 9-11 hours, supporting once-daily dosing. No dosage adjustment is required for renal impairment, but adjustment is required for moderate hepatic impairment.

Caspogin is for intravenous infusion only and must be reconstituted and further diluted before use (see Reconstitution). Administer by slow IV infusion over approximately 1 hour; do not administer as a bolus. Do not mix or co-infuse with dextrose-containing diluents, as caspofungin is not stable in dextrose-containing solutions. It should be given only under the supervision of a qualified healthcare professional in a hospital or specialist setting, with the infusion rate slowed if infusion-related reactions occur.

Cyclosporine

Concomitant use of Caspogin with cyclosporine may increase caspofungin plasma levels and has been associated with transient elevations in liver enzymes; concurrent use is not generally recommended unless the potential benefit outweighs the risk, and liver function should be closely monitored.

Tacrolimus

Caspogin reduces tacrolimus blood concentrations; tacrolimus levels should be monitored and the tacrolimus dose adjusted accordingly during co-administration.

Enzyme Inducers (rifampin, efavirenz, nevirapine, phenytoin, dexamethasone, carbamazepine)

These drugs can lower plasma concentrations of Caspogin through increased clearance; an increase in the maintenance dose of Caspogin to 70 mg daily should be considered with sustained co-administration.

Because of these clinically significant interactions, a full medication history should be reviewed before starting Caspogin, and liver function should be monitored during concurrent therapy with any hepatotoxic agent.

Common

• Fever
• Infusion-site reactions (phlebitis/thrombophlebitis)
• Headache
• Nausea, vomiting, diarrhea, abdominal pain
• Elevated liver enzymes (transaminases, alkaline phosphatase)
• Rash, pruritus
• Hypokalemia
• Chills

Serious (less common)

• Anaphylaxis and other serious hypersensitivity reactions
• Histamine-mediated infusion reactions (facial swelling, bronchospasm, generalized rash, flushing) - see Precautions
• Significant hepatotoxicity, including hepatitis and, rarely, hepatic failure - see Precautions
• Rare severe cutaneous reactions (e.g., Stevens-Johnson syndrome)

Patients should seek prompt medical attention for signs of a serious reaction while receiving Caspogin.

Pregnancy: Animal reproduction studies with Caspogin have shown adverse fetal effects at clinically relevant exposures, and there are no adequate, well-controlled studies in pregnant women. Caspogin should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; consult a physician before use in pregnancy.

Lactation: It is not known whether Caspogin is excreted in human breast milk. Because many drugs are excreted in breast milk and a risk to the nursing infant cannot be excluded, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother; consult a physician.

Hepatotoxicity

Elevations in liver enzymes and, rarely, clinically significant hepatic dysfunction (including hepatitis and hepatic failure) have been reported with Caspogin, particularly in patients with pre-existing hepatic impairment, those on concurrent hepatotoxic medications, or those receiving cyclosporine (see Drug Interactions). Liver function should be monitored during treatment, with dose reassessment if significant or progressive elevations occur.

Infusion-Related and Hypersensitivity Reactions

Histamine-mediated reactions, including rash, facial swelling, pruritus, sensation of warmth, and bronchospasm, can occur during infusion of Caspogin. Slowing the infusion rate may reduce these reactions. Anaphylaxis has been reported; discontinue immediately and provide appropriate treatment if a serious hypersensitivity reaction occurs.

Drug Interactions

Clinically significant interactions exist with cyclosporine, tacrolimus, rifampin and other enzyme inducers; see Drug Interactions for details and required dose adjustments.

Specialist / Inpatient Management

Caspogin is used to treat serious, often life-threatening fungal infections and requires management by, or in consultation with, a specialist in infectious disease, typically in an inpatient setting with appropriate monitoring.

Antifungal Stewardship

Take Caspogin exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice. Caspogin should be reserved for confirmed or strongly suspected serious systemic fungal infections, or appropriate empiric use in defined high-risk febrile neutropenic settings, and should not be used for superficial or minor fungal infections.

There is no specific antidote for Caspogin overdose, and it is not significantly removed by hemodialysis. In case of a suspected overdose, supportive treatment should be provided and the patient should seek immediate medical attention or contact emergency services or a poison control center; do not attempt unsupervised home management.

Store unopened vials of Caspogin refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light and keep out of reach of children. After reconstitution and dilution, follow the healthcare facility's protocol for storage time and temperature of the prepared infusion solution; do not freeze reconstituted or diluted solutions.

Renal Impairment

No dosage adjustment of Caspogin is required in patients with any degree of renal impairment, including those on hemodialysis.

Hepatic Impairment

Dose reduction is required in adults with moderate hepatic impairment (35 mg daily maintenance dose after the standard loading dose); data in severe hepatic impairment are limited, and Caspogin should be used with caution in this population (see Dosage and Administration).

Elderly

Modestly higher plasma exposure to Caspogin has been observed in elderly patients, but no dedicated dosage adjustment is generally recommended based on age alone; use with appropriate clinical monitoring.

Pediatric Patients

See Pediatric Uses for weight/body-surface-area-based dosing information.

Duration of treatment with Caspogin is individualized based on the indication, severity of infection, and clinical/microbiological response, and should be determined by the treating specialist. As general guidance: therapy for candidemia is typically continued for at least 14 days after the first negative blood culture and resolution of signs/symptoms of infection; esophageal candidiasis is typically treated for approximately 7-14 days, continuing for at least 7 days after symptom resolution; invasive aspergillosis and empirical therapy in febrile neutropenia are continued based on resolution of neutropenia and clinical response, as judged by the treating physician.

Caspogin powder for injection must be reconstituted before dilution and administration. Allow the refrigerated vial to reach room temperature. Reconstitute the vial with the volume of sterile Water for Injection specified on the product labeling (commonly 10.8 mL) and gently swirl until a clear solution forms; do not shake vigorously. The reconstituted solution must then be further diluted in 0.9% Sodium Chloride Injection (normal saline) for infusion. Do NOT use diluents containing dextrose (glucose), as Caspogin is not stable in dextrose-containing solutions. Inspect visually for particulate matter or discoloration prior to administration; discard if present.

Echinocandin antifungal; systemic antifungal agent.

Caspofungin Acetate acts by non-competitively inhibiting 1,3-β-D-glucan synthase, blocking synthesis of 1,3-β-D-glucan, a critical structural component of the fungal cell wall in susceptible Candida and Aspergillus species. This disrupts cell wall integrity, leading to osmotic lysis (fungicidal effect against Candida) or growth inhibition at actively dividing hyphal tips (fungistatic effect against Aspergillus). Because human cells lack a cell wall and do not synthesize 1,3-β-D-glucan, this mechanism provides fungal selectivity.

C

Caspogin is approved for use in pediatric patients 3 months to 17 years of age for empirical therapy of presumed fungal infections in febrile, neutropenic patients, treatment of candidemia and other Candida infections, and treatment of esophageal candidiasis, using body-surface-area (BSA)-based dosing: a 70 mg/m² loading dose on Day 1 (not to exceed 70 mg), followed by 50 mg/m² once daily thereafter (not to exceed 70 mg/day regardless of calculated dose), adjusted for hepatic impairment where applicable. Safety and efficacy of Caspogin have not been established in neonates and infants younger than 3 months, and data in this age group are limited; use in this population should only be under specialist guidance.